The Journal of Urology
Volume 179, Issue 2 , Pages 616-621 , February 2008

The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study

  • Claus G. Roehrborn

      Affiliations

    • Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationCorrespondence: Department of Urology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Moss Clinical Science Building (J) 8 142, Dallas, Texas 75390-9110 (telephone: 001-214-648-2941; FAX: 001-214-648-0365).
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Paul Siami

      Affiliations

    • Welborn Clinic, Evansville, Indiana
    • Financial interest and/or other relationship with Pfizer, GlaxoSmithKline, Astellas, Merck and Indevus.
    • ,
  • Jack Barkin

      Affiliations

    • Department of Urology, University of Toronto, Toronto, Ontario, Canada
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Ronaldo Damião

      Affiliations

    • Serviço de Urologia, Hospital Universitário Pedro Ernesto-Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Kim Major-Walker

      Affiliations

    • Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Betsy Morrill

      Affiliations

    • Research and Development, GlaxoSmithKline, Research Triangle Park, North Carolina
    • Financial interest and/or other relationship with GlaxoSmithKline.
    • ,
  • Francesco Montorsi

      Affiliations

    • Department of Urology, Universita Vita Salute San Raffaele, Milan, Italy
    • Financial interest and/or other relationship with Pfizer, Eli Lilly, Bayer, Pierre Fabre and GlaxoSmithKline.
    • ,
  • CombAT Study Group

Received 30 June 2007

References 

  1. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119
  2. Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996;335:533
  3. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387
  4. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179
  5. Siami P, Roehrborn CG, Barkin J, Damião R, Wyczolkowski M, Duggan A, et al. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart® and Tamsulosin) trial rationale and study design. Contemp Clin Trials. 2007;28:770
  6. Blouin MC, Blouin J, Perreault S, Lapointe A, Dragomir A. Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. J Cataract Refract Surg. 2007;33:1227
  7. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434
  8. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol. 2006;176:1529
  9. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92:1659
  10. Andriole GL, Roehrborn C, Schulman C, Slawin KM, Somerville M, Rittmaster RS. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537
  11. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. J Urol. 2004;172:1314
  12. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, et al. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol. 2006;175:217

 For another article on a related topic see page 770.

 Supported by GlaxoSmithKline.

PII: S0022-5347(07)02586-4

doi: 10.1016/j.juro.2007.09.084

The Journal of Urology
Volume 179, Issue 2 , Pages 616-621 , February 2008

Article Tools

* Image Usage & Resolution